Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596230 · ClinicalTrials.gov registry record
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 7,797
- Enrollment target
NCT02596230: Completed study, sponsored by Boehringer Ingelheim.
NCT02596230 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 7,797 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02596230 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 7,797 participants
- Enrollment target
Study Summary
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for cross-sectional characterization of the VTE patient population. Objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for the occurrence of outcome events for up to one year.
Primary Outcome
Age in years of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment o
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,797 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2019-03-31 |
What the finished NCT02596230 record still lists
NCT02596230 is an observational study that tracks outcomes without assigning an intervention. Its 7,797 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02596230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02596230 about?
NCT02596230 is a clinical study titled "RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism". RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient po...
What is the current status of trial NCT02596230?
This trial is currently completed. The enrollment target is 7,797 participants. The study started on 2015-11-05. Estimated completion is 2019-03-31.
Who is sponsoring clinical trial NCT02596230?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06560398 · 7,649 participants · NA
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- NCT03848312 · 7,600 participants · Phase 3
Preventing Alzheimer's With Cognitive Training
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- NCT00898638 · 8,000 participants
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI